MediciNova (NASDAQ:MNOV) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Saturday.
Shares of MediciNova (MNOV) opened at $7.31 on Friday. MediciNova has a fifty-two week low of $4.40 and a fifty-two week high of $7.88.
MediciNova (NASDAQ:MNOV) last released its earnings results on Monday, October 23rd. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). sell-side analysts predict that MediciNova will post -0.37 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/20/medicinova-mnov-rating-lowered-to-hold-at-bidaskclub.html.
Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.